2023
Babesia BdFE1 esterase is required for the anti-parasitic activity of the ACE inhibitor fosinopril
Vydyam P, Choi J, Gihaz S, Chand M, Gewirtz M, Thekkiniath J, Lonardi S, Gennaro J, Mamoun C. Babesia BdFE1 esterase is required for the anti-parasitic activity of the ACE inhibitor fosinopril. Journal Of Biological Chemistry 2023, 299: 105313. PMID: 37797695, PMCID: PMC10663679, DOI: 10.1016/j.jbc.2023.105313.Peer-Reviewed Original ResearchConceptsAngiotensin converting enzyme (ACE) inhibitorsACE inhibitor fosinoprilTick-borne illnessConverting Enzyme InhibitorsVector-borne parasitic diseaseClass of drugsNovel drug targetsApicomplexan parasitesMass spectrometry analysisAnti-parasitic activityHeart failureSafe therapyParasite developmentDrug targetsEnzyme inhibitorsParasitic diseasesDrug resistanceTreatment of diseasesHuman babesiosisBabesia parasitesIntraerythrocytic parasitesSuch diseasesDiseaseSpectrometry analysisParasites
2022
A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors.
LoRusso P, Rasco D, Shapiro G, Mita A, Azad N, Swiecicki P, El-Khoueiry A, Gandara D, Kummar S, Tanajian H, Taylor J, Bottone F, Toguchi M, Hindley C, Chan D, Oganesian A, Keer H, Dao K, Sullivan R, Spira A. A first-in-human, phase 1 study of ASTX029, a dual-mechanism inhibitor of ERK1/2, in relapsed/refractory solid tumors. Journal Of Clinical Oncology 2022, 40: 9085-9085. DOI: 10.1200/jco.2022.40.16_suppl.9085.Peer-Reviewed Original ResearchRefractory solid tumorsPhase 1 studyCentral serous retinopathyDose levelsSolid tumorsPartial responseOpen-label phase 1 studyPhase 1bNon-small cell lung cancerTarget exposurePD effectsDose-limiting toxicity eventsPhase 2 dosePhase 2 studyPreliminary clinical activityCell lung cancerDaily dose levelsDose-escalation designDays of dosingFresh tumor biopsiesClass of drugsPhase 1aExtracellular signal-regulated kinase 1/2 (ERK1/2) inhibitorNSCLC subjectsOcular AEs
2020
CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction.
Abu-Khalaf M, Hatzis C, Hodge K, Valdes F, Sikov W, Mita M, Denduluri N, Awerkamp K, Murphy R, Zelterman D, Dunetz B, Petricoin E, Pierobon M. CDK 4/6 drug target activation mapping of HR+/HER2- metastatic breast cancer for treatment selection and response prediction. Journal Of Clinical Oncology 2020, 38: e13029-e13029. DOI: 10.1200/jco.2020.38.15_suppl.e13029.Peer-Reviewed Original ResearchMetastatic breast cancerBreast cancerCyclin D1CDK 4/6 inhibitorsBaseline tumor tissueClass of drugsAdjuvant settingEndocrine therapyTherapy initiationFrontline therapyInhibitor therapyPFS intervalStudy treatmentPredictive markerDisease progressionClinical trialsOutcome dataTreatment selectionPathway biomarkersBiopsy materialAverage age 62Tumor tissuePatientsFinal analysisTop quartileCan Recurrent Pregnancy Loss Be Prevented by Antithrombotic Agents?
Merriam A, Paidas M. Can Recurrent Pregnancy Loss Be Prevented by Antithrombotic Agents? 2020, 223-230. DOI: 10.1201/9780429450303-24.ChaptersRecurrent pregnancy lossPregnancy outcomesAntiplatelet agentsPregnancy lossAntithrombotic agentsMultiple adverse pregnancy outcomesSmall case-control studyAntiplatelet agent aspirinAdverse pregnancy outcomesSuccessful pregnancy outcomeCase-control studyMultiple prospective studiesHistory of thrombophiliaClass of drugsEffects of anticoagulantsAspirin treatmentProspective studyAnticoagulant agentsLive birthsThrombophiliaBlood clotsWomenAspirinOutcomesAgents
2019
Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment
Quagliato LA, Cosci F, Shader RI, Silberman EK, Starcevic V, Balon R, Dubovsky SL, Salzman C, Krystal JH, Weintraub SJ, Freire RC, Nardi AE, Benzodiazepines I. Selective serotonin reuptake inhibitors and benzodiazepines in panic disorder: A meta-analysis of common side effects in acute treatment. Journal Of Psychopharmacology 2019, 33: 1340-1351. PMID: 31304840, DOI: 10.1177/0269881119859372.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsMore adverse effectsPD treatmentPanic disorderReuptake inhibitorsRisk factorsClinical trialsAdverse effectsCochrane Central RegisterAdverse event ratesCommon side effectsShort-term treatmentClass of drugsWeb of ScienceAbnormal ejaculationLibido reductionDry mouthAdverse eventsCentral RegisterPharmacologic treatmentSSRI treatmentAcute treatmentControlled TrialsPrimary outcome
2017
Immunotherapy in Lung Cancer
Du L, Herbst RS, Morgensztern D. Immunotherapy in Lung Cancer. Hematology/Oncology Clinics Of North America 2017, 31: 131-141. PMID: 27912829, DOI: 10.1016/j.hoc.2016.08.004.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerAdvanced stage non-small cell lung cancerPD-1/PD-L1 axisFirst-line platinum-based doubletStage non-small cell lung cancerApproval of nivolumabPlatinum-based doubletsSecond-line docetaxelGood performance statusImmune checkpoint inhibitorsPD-L1 axisMinority of patientsRandomized clinical trialsTreatment of patientsNew therapeutic approachesClass of drugsCheckpoint inhibitorsOverall survivalPerformance statusClinical trialsProlonged benefitTherapeutic approachesPatients
2012
19IN Does Molecular Triage Help to Identify Highly Sensitive Disease?
Pusztai L. 19IN Does Molecular Triage Help to Identify Highly Sensitive Disease? Annals Of Oncology 2012, 23: ix29. DOI: 10.1016/s0923-7534(20)32633-8.Peer-Reviewed Original ResearchResponse markersPredictive valueEstrogen receptor expressionHigher tumor proliferationTreatment response markersClass of drugsNegative predictive valuePositive predictive valueDriver eventsAdjuvant therapyPredictive biomarkersPredictive markerTreatment modalitiesTriage patientsVariety of agentsBaseline prognosisClinical trialsReceptor expressionBreast cancerSensitive diseaseHuman epidermal growth factorClinical utilityEpidermal growth factorChemotherapy sensitivityTumor proliferation
2010
Mice lacking the galanin gene show decreased sensitivity to nicotine conditioned place preference
Neugebauer NM, Henehan RM, Hales CA, Picciotto MR. Mice lacking the galanin gene show decreased sensitivity to nicotine conditioned place preference. Pharmacology Biochemistry And Behavior 2010, 98: 87-93. PMID: 21172385, PMCID: PMC3030658, DOI: 10.1016/j.pbb.2010.12.015.Peer-Reviewed Original ResearchConceptsGal-/- miceAcute nicotine administrationNicotine CPPPlace preferenceNicotine administrationRewarding effectsRole of galaninEffects of nicotineNucleus accumbens shellClass of drugsAmphetamine place preferenceDrugs of abuseGalanin signalingNeuropeptide galaninCPP chamberAlcohol drinkingNicotine rewardSignificant CPPExtracellular signal-related kinaseAccumbens shellGalanin peptideHigh doseSystem activationAlcohol preferenceSignal-related kinase
2009
The Effect of Proton Pump-Inhibiting Drugs on Mineral Metabolism
Insogna KL. The Effect of Proton Pump-Inhibiting Drugs on Mineral Metabolism. The American Journal Of Gastroenterology 2009, 104: ajg200944. PMID: 19262542, DOI: 10.1038/ajg.2009.44.BooksConceptsProton pump inhibitorsMineral metabolismLong-term proton pump inhibitorsIntestinal calcium absorptionHip fracture ratesClass of drugsFragility fracturesBone lossCalcium economyPump inhibitorsCalcium absorptionFracture ratesCalcium balanceSkeletal homeostasisGreater riskAdverse effectsHigh rateDrugsRecent studiesMetabolismLong term
2005
Hypercalcemia in Breast Cancer: An Echo of Bone Mobilization During Lactation?
DeMauro S, Wysolmerski J. Hypercalcemia in Breast Cancer: An Echo of Bone Mobilization During Lactation? Journal Of Mammary Gland Biology And Neoplasia 2005, 10: 157-167. PMID: 16025222, DOI: 10.1007/s10911-005-5398-9.BooksConceptsBreast cancer patientsBone resorptionCancer patientsBreast cancerParathyroid hormone-related proteinPathophysiology of hypercalcemiaMultiple skeletal metastasesPathological bone resorptionHormone-related proteinActivation of osteoclastsSecretion of cytokinesClass of drugsSkeletal calcium storesNormal breast cellsFrequent complicationSkeletal metastasesSignificant morbidityCalcium metabolismCurrent therapiesHypercalcemiaNew therapiesCalcium levelsOsteoclast differentiationCalcium storesPatients
2004
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial
Jamerson K, Bakris G, Wun C, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, Velazquez E, Weber M. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial. American Journal Of Hypertension 2004, 17: 793-801. PMID: 15363822, DOI: 10.1016/j.amjhyper.2004.05.004.Peer-Reviewed Original ResearchConceptsSystolic Hypertension (ACCOMPLISH) trialCardiovascular eventsBlood pressureHypertension trialsCombination therapyOptimal BP controlPrimary study endpointCalcium channel blockersClass of drugsBP controlCardiovascular outcomesHypertensive patientsPrimary endpointCardiovascular mortalityStudy endpointACE inhibitorsHypertension managementFirst patientClinical eventsAntihypertensive combinationsRisk factorsSuch therapyRecent guidelinesDrug classesVasculoprotective properties
2001
Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins?
Sessa W. Can modulation of endothelial nitric oxide synthase explain the vasculoprotective actions of statins? Trends In Molecular Medicine 2001, 7: 189-191. PMID: 11325618, DOI: 10.1016/s1471-4914(01)01985-2.Peer-Reviewed Original ResearchConceptsEndothelial nitric oxide synthaseMainstay of therapyCoronary artery diseaseLipid-lowering effectsNitric oxide synthaseNitric oxide synthesisClass of drugsNitric oxide releaseArtery diseaseVasculoprotective actionsOxide synthaseBeneficial actionsOxide synthesisOxide releaseCellular mechanismsStatinsDrugsRecent insightsTherapyMainstayDisease
1999
Comparative Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Antagonism on Plasma Fibrinolytic Balance in Humans
Brown N, Agirbasli M, Vaughan D. Comparative Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Type 1 Receptor Antagonism on Plasma Fibrinolytic Balance in Humans. Hypertension 1999, 34: 285-290. PMID: 10454455, DOI: 10.1161/01.hyp.34.2.285.Peer-Reviewed Original ResearchMeSH KeywordsAdultAldosteroneAngiotensin IIAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBlood PressureData Interpretation, StatisticalDiet, Sodium-RestrictedFemaleFibrinolysisHeart RateHumansIsoquinolinesLosartanMalePlasminogen Activator Inhibitor 1QuinaprilReninRenin-Angiotensin SystemTetrahydroisoquinolinesTissue Plasminogen ActivatorConceptsPlasminogen activator inhibitor-1PAI-1 antigenTissue plasminogen activatorACE inhibitorsFibrinolytic balanceAldosterone systemAngiotensin II type 1 receptor antagonismAngiotensin II type 1 receptor antagonistAngiotensin-Converting Enzyme InhibitionType 1 receptor antagonistPlasma PAI-1 antigenPAI-1 antigen concentrationsAntigen concentrationEquivalent hypotensive dosesPlasma fibrinolytic balancePlasma renin activityAngiotensin II formationLow salt intakePAI-1 activityClass of drugsTPA antigen concentrationsActivator inhibitor-1Enzyme inhibitionLosartan treatmentQuinapril treatment
1998
A Model for Improving Medication Use in Home Health Care Patients
Brown N, Griffin M, Ray W, Meredith S, Beers M, Marren J, Robles M, Stergachis A, Wood A, Avorn J. A Model for Improving Medication Use in Home Health Care Patients. Journal Of The American Pharmacists Association 1998, 38: 696-702. PMID: 9861787, DOI: 10.1016/s1086-5802(16)30390-4.Peer-Reviewed Original ResearchConceptsHome health nursesHome health careMedication useMedication problemsHealth nursesCare settingsHome health care patientsPotential medication problemsSuboptimal medication useHome health nursingHome health care settingHealth careHealth care patientsSpecific adverse effectsClass of drugsHealth care settingsHome care settingHealth services researchElderly patientsCare patientsClinical signsClinical pharmacologyHealth nursingExpert panel reviewDrug use
1987
Clinical Pharmacokinetics of Anti-Parkinsonian Drugs
Cedarbaum J. Clinical Pharmacokinetics of Anti-Parkinsonian Drugs. Clinical Pharmacokinetics 1987, 13: 141-178. PMID: 3311529, DOI: 10.2165/00003088-198713030-00002.Peer-Reviewed Original ResearchConceptsAnti-parkinsonian agentsAnti-parkinsonian drugsClinical PharmacokineticsParkinson's diseaseDirect acting dopamine receptor agonistsLarge neutral amino acidsResponse fluctuationsAnti-parkinsonian actionLittle pharmacokinetic dataPharmacodynamics of levodopaTherapeutic response fluctuationsPlasma levodopa concentrationsDopamine receptor agonistsPotential drug toxicityClass of drugsMechanism of actionParkinsonian populationRenal functionPharmacokinetic considerationsUnchanged drugBrain uptakeReceptor agonistRenal excretionShort eliminationLevodopa concentrations
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply